Cost Management Insights: SG&A Expenses for GSK plc and Perrigo Company plc

SG&A Expenses: GSK vs. Perrigo's Strategic Insights

__timestampGSK plcPerrigo Company plc
Wednesday, January 1, 20148246000000675200000
Thursday, January 1, 20159232000000771800000
Friday, January 1, 201693660000001205500000
Sunday, January 1, 201796720000001146500000
Monday, January 1, 201899150000001125800000
Tuesday, January 1, 2019114020000001166100000
Wednesday, January 1, 2020114560000001175500000
Friday, January 1, 2021109750000001111400000
Saturday, January 1, 202283720000001210100000
Sunday, January 1, 202393850000001274600000
Loading chart...

Igniting the spark of knowledge

Navigating SG&A Expenses: A Tale of Two Giants

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: GSK plc and Perrigo Company plc, from 2014 to 2023. Over this period, GSK's SG&A expenses fluctuated, peaking in 2020 with a 39% increase from 2014, before a notable dip in 2022. Meanwhile, Perrigo's expenses showed a steady upward trend, culminating in a 47% rise by 2023. This divergence highlights differing strategic approaches to cost management. GSK's volatility may reflect strategic shifts or market challenges, while Perrigo's consistent growth suggests a stable expansion strategy. Understanding these trends offers valuable insights into the financial health and strategic priorities of these pharmaceutical leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025